What oral therapy is recommended for a girl with lichen planus?

Oral Lichen Planus Treatment in Girls

For a girl with oral lichen planus, start with high-potency topical corticosteroids (clobetasol 0.05% gel or dexamethasone 0.5 mg/5 mL elixir) applied twice daily to affected areas, and if this fails after 2-3 months or symptoms are severe, add oral hydroxychloroquine 400 mg daily or systemic corticosteroids (prednisone 30-60 mg daily for 1 week with tapering). 1, 2, 3

First-Line Topical Therapy

Begin with topical high-potency corticosteroids as the cornerstone of treatment:

• Clobetasol 0.05% gel for oral mucosal lesions (gel formulation penetrates mucosa better than cream/ointment) 1
• Dexamethasone 0.5 mg/5 mL elixir as mouth rinse for multiple or difficult-to-reach oral locations 4
• Fluocinonide 0.05% gel as alternative 1
• Apply twice daily for 2-3 months, then taper gradually if symptoms improve 5

Alternative topical option: Tacrolimus 0.1% ointment can be used if corticosteroids are contraindicated or ineffective 1

Important Caveats for Topical Steroids

• Avoid potent steroids in very young pediatric patients due to risk of cutaneous atrophy, adrenal suppression, and hypopigmentation 5
• Counsel on aggressive hand washing after application to prevent spreading to eyes or other sensitive areas 5
• Disease may resume when topical treatment stops 5

Systemic Therapy for Moderate-to-Severe Disease

When topical therapy fails or symptoms are highly symptomatic, escalate to systemic treatment:

Oral Corticosteroids (For Rapid Control)

• Prednisone 30-60 mg daily (or 1 mg/kg) for 1 week, followed by dose tapering over the second week 4
• Use for highly symptomatic ulcers or recurrent lesions 4
• This provides quick symptom control before transitioning to steroid-sparing agents

Hydroxychloroquine (Preferred Steroid-Sparing Agent)

• Hydroxychloroquine 400 mg daily 2, 3
• Evidence shows 81% response rate (24% complete remission, 57% moderate-to-marked improvement) in erosive oral lichen planus 3
• Response typically observed after 2-4 months 3
• Critical monitoring: Check for visual field defects, elevated creatinine, and hyperpigmentation 3
• Relatively safe with manageable side effect profile compared to other systemic options

Alternative Systemic Options

Acitretin (if no childbearing potential):

• 30 mg daily showed marked improvement in 64% vs 13% on placebo 2
• 83% of patients with mucocutaneous disease improved significantly 2
• Absolute contraindication in females of childbearing potential due to severe teratogenic risk and prolonged elimination (converts to etretinate with alcohol exposure) 6, 2
• Reserve for severe, refractory cases in post-menopausal women or males

Other steroid-sparing immunosuppressants for refractory cases 1:

• Azathioprine
• Cyclosporine (avoid if any neurological symptoms due to neurotoxicity risk) 7
• Methotrexate
• Mycophenolate mofetil

Adjunctive Supportive Care

Implement these measures for all patients:

• Good oral hygiene: Twice-daily tooth brushing, chlorhexidine or fluoride rinse if brushing too painful 1
• Dietary modifications: Avoid crunchy, spicy, acidic foods and hot beverages 1
• Pain management:
  • Viscous lidocaine 2% or "magic mouthwash" (diphenhydramine + antacid + viscous lidocaine in equal parts) before meals 4, 1
  • Coating agents like sucralfate 7
• Acid suppression: Consider PPI or H2 blocker 1

Treatment Algorithm

1. Mild disease: Topical high-potency corticosteroids (clobetasol 0.05% gel) BID × 2-3 months
2. Moderate disease: Add oral antihistamines + consider systemic corticosteroids for rapid control, then transition to hydroxychloroquine 400 mg daily
3. Severe/refractory disease: Systemic corticosteroids + hydroxychloroquine, or consider other immunosuppressants (azathioprine, mycophenolate mofetil, methotrexate)
4. Post-menopausal or severe refractory cases: Consider acitretin 30 mg daily (never in females of childbearing potential)

Critical Monitoring

• Follow-up at 2-4 months to assess response to hydroxychloroquine 3
• Long-term surveillance for malignant transformation (1.43% baseline risk, 5.13% with dysplasia) 8
• Biopsy non-healing lesions to rule out malignancy 5
• If using hydroxychloroquine: monitor visual fields, renal function, and skin pigmentation 3

The evidence strongly supports starting with topical corticosteroids and escalating to hydroxychloroquine for systemic therapy, as this provides the best balance of efficacy and safety in female patients where teratogenic risk must be avoided.